Equities analysts expect Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to post ($0.53) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Anthera Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.46). Anthera Pharmaceuticals reported earnings per share of ($0.86) during the same quarter last year, which suggests a positive year-over-year growth rate of 38.4%. The company is scheduled to report its next quarterly earnings report on Wednesday, August 8th.
According to Zacks, analysts expect that Anthera Pharmaceuticals will report full year earnings of ($2.28) per share for the current year, with EPS estimates ranging from ($2.37) to ($2.19). For the next year, analysts anticipate that the company will post earnings of ($1.78) per share, with EPS estimates ranging from ($2.02) to ($1.54). Zacks’ EPS calculations are an average based on a survey of research firms that cover Anthera Pharmaceuticals.
Several equities research analysts have weighed in on ANTH shares. Zacks Investment Research cut shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, February 21st. Jefferies Financial Group restated a “hold” rating and issued a $0.50 price objective on shares of Anthera Pharmaceuticals in a research report on Thursday, March 15th. Roth Capital started coverage on shares of Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They issued a “buy” rating and a $10.00 price objective for the company. ValuEngine upgraded shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Finally, Piper Jaffray Companies cut shares of Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a research report on Monday, March 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $3.44.
ANTH traded down $0.01 during midday trading on Friday, hitting $0.31. The company had a trading volume of 658,100 shares, compared to its average volume of 1,994,474. The stock has a market capitalization of $7.62 million, a PE ratio of -0.08 and a beta of 2.69. Anthera Pharmaceuticals has a twelve month low of $0.21 and a twelve month high of $2.97.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.